Top

European Journal of Medical Research

Published in:

Open Access 01-12-2015 | Research

CD146 as an adverse prognostic factor in uterine sarcoma

Authors: Yun Zhou, He Huang, Lin-Jing Yuan, Ying Xiong, Xin Huang, Jia-Xin Lin, Min Zheng

Published in: European Journal of Medical Research | Issue 1/2015

Abstract

Background

Uterine sarcoma is an aggressive malignancy with a poor prognosis. This study aimed to determine the expression of CD146, P53, and Ki-67 in uterine sarcoma and to evaluate their prognostic significance.

Methods

We retrospectively analyzed the prognosis and clinicopathologic features of 68 patients with uterine sarcoma. Immunohistochemical analyses of CD146, P53, and Ki-67 were performed in tissue samples collected from these patients and their relationship with prognosis was investigated.

Results

The 5-year overall survival (OS) rate was 46 %. Endometrial stromal sarcoma (ESS) patients had a better prognosis than leiomyosarcoma (LMS) patients, with a 2-year survival rate of 82 %. The membrane and cytoplasm of tumor cells exhibited CD146 overexpression in 8 (32 %) ESS cases, which was less than the 25 (69.4 %) cases observed in LMS and 2 (28.6 %) in MMMT. CD146 overexpression in the membrane and cytoplasm of tumor cells was closely related to lymph node metastasis (P = 0.021) and Ki-67 overexpression (P = 0.0053); there was no significant correlation with age, tumor size, International Federation of Obstetrics and Gynecology stage, or P53 overexpression in LMS.

Conclusions

CD146, P53, and Ki-67 are overexpressed in uterine sarcoma. CD146 expression correlates with lymph node metastasis and is associated with poor OS in LMS; it may be a potential prognostic marker for LMS.

Mundhenke C, Bauerschlag D, Fischer D, Friedrich M, Maass N (2007) Malignant tumors of the uterus. Ther Umsch 64:381–388CrossRefPubMed

Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I (2009) Clinical management of uterine sarcomas. Lancet Oncol 10:1188–1198CrossRefPubMed

Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT et al (2008) Prognostic factors and treatment outcomes of patients with uterine sarcoma analysis of 127 patients at a single institution. J Cancer Res Clin Oncol 134:1277–1287CrossRefPubMed

Trope CG, Abeler VM, Kristensen GB (2012) Diagnosis and treatment of sarcoma of the uterus. a review. Acta Oncol 51:694–705CrossRefPubMed

Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A et al (2007) Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 25:5240–5247CrossRefPubMed

Bur ME et al (1992) P53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 98(1):81–87PubMed

Niemann TH et al (1995) P53 protein overexpression in smooth muscle tumors of the uterus. Hum Pathol 26(4):375–379CrossRefPubMed

Zhai YL et al (1999) Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol 18(1):20–28CrossRefPubMed

Mayerhofer K et al (2004) Ki-67 and vascular endothelial growth factor expression in uterine leiomyosarcoma. Gynecol Oncol 92(1):175–179CrossRefPubMed

10.

Lehmann JM, Riethmuller G, Johnson JP (1989) MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 86(24):9891–9895PubMedCentralCrossRefPubMed

11.

Aldovini D et al (2006) M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer 119(8):1920–1926CrossRefPubMed

12.

Zabouo G et al (2009) CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res 11(1):R1PubMedCentralCrossRefPubMed

13.

Liu WF et al (2012) CD146 expression correlates with epithelial–mesenchymal transition markers and a poor prognosis in gastric cancer. Int J Mol Sci 13(5):6399–6406PubMedCentralCrossRefPubMed

14.

Zhang H et al (2013) CD146 is a potential marker for the diagnosis of malignancy in cervical and endometrial cancer. Oncol Lett 5(4):1189–1194PubMedCentralPubMed

15.

Ouhtit A et al (2009) Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. Biochim Biophys Acta 1795(2):130–136PubMed

16.

Yan X et al (2003) A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 102(1):184–191CrossRefPubMed

17.

Zheng M et al (2010) Overexpression of karyopherin-2 in epithelial ovarian cancer and correlation with poor prognosis. Obstet Gynecol 116(4):884–891CrossRefPubMed

18.

Durnali A et al (2012) Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey. Asian Pac J Cancer Prev 13(5):1935–1941CrossRefPubMed

19.

Denschlag D et al (2007) Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol 33(1):91–95CrossRefPubMed

20.

Kim SH et al (2006) Prognostic factors and expression of p53 and mdm-2 in uterine sarcomas. Int J Gynaecol Obstet 95(3):272–277CrossRefPubMed

21.

Major FJ et al (1993) Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71(4 Suppl):1702–1709CrossRefPubMed

22.

Zeng Q et al (2012) CD146, an epithelial–mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci USA 109(4):1127–1132PubMedCentralCrossRefPubMed

23.

Johnson JP, Rothbacher U, Sers C (1993) The progression associated antigen MUC18: a unique member of the immunoglobulin supergene family. Melanoma Res 3(5):337–340CrossRefPubMed

24.

Rovirosa A et al (2002) Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages. Int J Radiat Oncol Biol Phys 52(5):1320–1329CrossRefPubMed

Title: CD146 as an adverse prognostic factor in uterine sarcoma
Authors: Yun Zhou
He Huang
Lin-Jing Yuan
Ying Xiong
Xin Huang
Jia-Xin Lin
Min Zheng
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 1/2015
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-015-0160-2

ACC 2024 Congress

Springer Medicine

CD146 as an adverse prognostic factor in uterine sarcoma

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Primary epididymis malignant triton tumor: case report and review of the literature

Effects of synthetic colloid and crystalloid solutions on hemorheology in vitro and in hemorrhagic shock

“Different trend” in multiple primary lung cancer and intrapulmonary metastasis

Perceptions of normal and abnormal ejaculatory latency times: an observational study in Ghanaian males and females

Specific microRNAs as novel biomarkers for combination chemotherapy resistance detection of colon adenocarcinoma

Better short-term efficacy of treating severe flail chest with internal fixation surgery compared with conservative treatments